Xencor stock falls 1.57 percent as BofA raises target

Published on 09/25/2026 at 09:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xencor stock trades at USD 23.88 on Nasdaq on September 24, 2026, 22.0 percent below its 52-week high. Second-quarter revenue reached USD 51.22 million, up 17.4 percent year over year.

Xencor stock, biotechnology, analyst target, clinical pipeline, Nasdaq, Illustration mit AI erstellt.

Xencor stock (ISIN US98401H1023) stood at USD 23.88 on Nasdaq on September 24, 2026, down 1.57 percent for the session. The immediate market reference is Bank of America, which raised its price target from USD 20 to USD 26 while keeping a Neutral rating on September 21, 2026, according to MarketBeat.

Target rises to USD 26

The move puts the new target USD 2.12 above the September 24 market price. That is a concrete shift in valuation framing, although the Neutral rating keeps the message balanced rather than turning it into a bullish call.

The analyst update follows Xencor's second-quarter report, which showed adjusted EPS of negative USD 0.29 against a negative USD 0.80 consensus estimate. The USD 0.51 improvement versus expectations came with revenue of USD 51.22 million, up 17.4 percent from the prior-year quarter, according to MarketBeat.

Pipeline milestones set the rhythm

Xencor's operating story remains tied to clinical progress rather than recurring commercial sales. The company described XmAb819 expansion cohorts in clear cell renal cell carcinoma and enrollment progress for XmAb942 in its XENITH-UC study in the August 5, 2026 second-quarter release available through Xencor.

That mix explains why the revenue comparison matters but does not settle the valuation question. For a clinical-stage biotechnology company, the next meaningful re-rating input is likely to come from trial execution and data quality, while the latest quarter provides a measurable financial cushion.

Stock remains below yearly high

At USD 23.88 on Nasdaq on September 24, 2026, Xencor remained USD 6.73 below its 52-week high of USD 30.61, a 22.0 percent gap. Market capitalization was USD 1.77 billion as of the same quote date, giving the USD 26 target a direct reference against a company valued below USD 2 billion.